Cover Image
市場調查報告書

肝癌:開發中產品分析

Hepatocellular Carcinoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229736
出版日期 內容資訊 英文 960 Pages
訂單完成後即時交付
價格
Back to Top
肝癌:開發中產品分析 Hepatocellular Carcinoma - Pipeline Review, H2 2016
出版日期: 2016年11月30日 內容資訊: 英文 960 Pages
簡介

肝細胞癌(HCC)是有女性比男性更容易罹患這個趨勢的癌症,其症狀有腹部(尤其是右上部)的疼痛、容易長出痣、容易出血、腹部膨脹感、黃膽等。罹患肝細胞癌的主要原因有大量攝取酒精、肝臟自體的兔疫疾病、B型或C型肝炎病毒的感染、長期(慢性)的肝臟發炎、體內積蓄過多鐵質(血色素沉著病)等。

本報告提供肝癌治療藥的開發中產品概要和臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

肝癌概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

肝癌:企業開發中的治療藥

肝癌:大學/機關研究中的治療藥

肝癌:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

肝癌:企業開發中的產品

肝癌:大學/機關研究中的產品

肝癌的治療藥的開發企業

肝癌:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

肝癌:最近的開發平台趨勢

肝癌:暫停中的計劃

肝癌:開發中止的產品

肝癌:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8748IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatocellular Carcinoma - Pipeline Review, H2 2016, provides an overview of the Hepatocellular Carcinoma (Oncology) pipeline landscape.

Hepatocellular carcinoma (HCC) is a type of cancer originates from a liver cell (hepatocyte) which becomes cancerous. This type of cancer occurs more often in men than women. Symptoms include abdominal pain or tenderness, especially in the upper-right part, easy bruising or bleeding, enlarged abdomen and yellow skin or eyes (jaundice). The predisposing factors include alcohol abuse, autoimmune diseases of the liver, hepatitis B or C virus infection, inflammation of the liver that is long-term (chronic) and iron overload in the body (hemochromatosis). Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatocellular Carcinoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatocellular Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 16, 69, 42, 4, 62 and 14 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 8, 4, 1, 21 and 2 molecules, respectively.Hepatocellular Carcinoma.

Hepatocellular Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Hepatocellular Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatocellular Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatocellular Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatocellular Carcinoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatocellular Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Hepatocellular Carcinoma Overview
  • Therapeutics Development
  • Hepatocellular Carcinoma - Therapeutics under Development by Companies
  • Hepatocellular Carcinoma - Therapeutics under Investigation by Universities/Institutes
  • Hepatocellular Carcinoma - Pipeline Products Glance
  • Hepatocellular Carcinoma - Products under Development by Companies
  • Hepatocellular Carcinoma - Products under Investigation by Universities/Institutes
  • Hepatocellular Carcinoma - Companies Involved in Therapeutics Development
  • Hepatocellular Carcinoma - Therapeutics Assessment
  • Drug Profiles
  • Hepatocellular Carcinoma - Dormant Projects
  • Hepatocellular Carcinoma - Discontinued Products
  • Hepatocellular Carcinoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Hepatocellular Carcinoma, H2 2016
  • Number of Products under Development for Hepatocellular Carcinoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Hepatocellular Carcinoma - Pipeline by 4SC AG, H2 2016
  • Hepatocellular Carcinoma - Pipeline by AB Science SA, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Acceleron Pharma Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by ACROVIS Pharma AG, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Advenchen Laboratories LLC, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Alfact Innovation, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Amgen Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by AndroScience Corp, H2 2016
  • Hepatocellular Carcinoma - Pipeline by ArQule Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Array BioPharma Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Astellas Pharma Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Astex Pharmaceuticals Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by AstraZeneca Plc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by AVEO Pharmaceuticals Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Bayer AG, H2 2016
  • Hepatocellular Carcinoma - Pipeline by BeiGene Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Bioneer Corp, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Blueprint Medicines Corp, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Boston Biomedical Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Can-Fite BioPharma Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by CASI Pharmaceuticals Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by CCRP Therapeutics GmbH, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Celgene Corp, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Celldex Therapeutics Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Celsion Corp, H2 2016
  • Hepatocellular Carcinoma - Pipeline by China Medical System Holdings Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Chroma Therapeutics Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Delcath Systems Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Double Bond Pharmaceutical International AB, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Eisai Co Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Eli Lilly and Company, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Endocyte Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Epeius Biotechnologies Corp, H2 2016
  • Hepatocellular Carcinoma - Pipeline by eTheRNA Immunotherapies NV, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Exelixis Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Faron Pharmaceuticals Oy, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Galaxy Biotech LLC, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Genelux Corp, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Genoscience Pharma, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Genosco, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Gilead Sciences Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Golden Biotechnology Corp, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Green Cross Cell Corp, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Green Cross Corp, H2 2016
  • Hepatocellular Carcinoma - Pipeline by H3 Biomedicine Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by HanAll Biopharma Co Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by HEC Pharm Co., Ltd., H2 2016
  • Hepatocellular Carcinoma - Pipeline by Horizon Pharma Plc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Immune Therapeutics, Inc., H2 2016
  • Hepatocellular Carcinoma - Pipeline by Immunicum AB, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Immunitor Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Immunomedics Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Immunovative Therapies Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by In-Cell-Art SAS, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Inovio Pharmaceuticals Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Inspyr Therapeutics Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by InteRNA Technologies BV, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Jenrin Discovery Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Johnson & Johnson, H2 2016
  • Hepatocellular Carcinoma - Pipeline by KAHR medical Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Karcinolys SAS, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Kite Pharma Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Komipharm International Co Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Kowa Company Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Les Laboratoires Servier SAS, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Ligand Pharmaceuticals Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by MaxCyte Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by MedImmune LLC, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Medivation Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Medivir AB, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Merck & Co Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Merck KGaA, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Midatech Pharma Plc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Mina Therapeutics Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Molecular Partners AG, H2 2016
  • Hepatocellular Carcinoma - Pipeline by MolMed SpA, H2 2016
  • Hepatocellular Carcinoma - Pipeline by MultiCell Technologies Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by NormOxys Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Novartis AG, H2 2016
  • Hepatocellular Carcinoma - Pipeline by NovaTarg Therapeutics Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Nymox Pharmaceutical Corp, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Omeros Corp, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Oncolys BioPharma Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by OncoMed Pharmaceuticals Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by OncoTherapy Science Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Oneness Biotech Co Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Onxeo SA, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Otsuka Holdings Co Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Panacea Pharmaceuticals Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by PepVax Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Pfizer Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Pharma Mar SA, H2 2016
  • Hepatocellular Carcinoma - Pipeline by PharmAbcine Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by PharmaEssentia Corp, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Provecs Medical GmbH, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Provectus Biopharmaceuticals Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by RedHill Biopharma Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Regulus Therapeutics Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Rigontec GmbH, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Saronic Biotechnology Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Shenogen Pharma Group Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H2 2016
  • Hepatocellular Carcinoma - Pipeline by Sillajen Biotherapeutics, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Taiwan Liposome Company Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2016
  • Hepatocellular Carcinoma - Pipeline by TC BioPharm Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Therapure Biopharma Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Theravectys SA, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Threshold Pharmaceuticals Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Tiziana Life Sciences Plc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by TRACON Pharmaceuticals Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Tumorend LLC, H2 2016
  • Hepatocellular Carcinoma - Pipeline by UbiVac LLC, H2 2016
  • Hepatocellular Carcinoma - Pipeline by VasGene Therapeutics Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Vaxon Biotech, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Vect-Horus SAS, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Verlyx Pharma Inc, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Vicus Therapeutics LLC, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Virttu Biologics Ltd, H2 2016
  • Hepatocellular Carcinoma - Pipeline by Vyriad Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hepatocellular Carcinoma - Dormant Projects, H2 2016
  • Hepatocellular Carcinoma - Dormant Projects (Contd..1), H2 2016
  • Hepatocellular Carcinoma - Dormant Projects (Contd..2), H2 2016
  • Hepatocellular Carcinoma - Dormant Projects (Contd..3), H2 2016
  • Hepatocellular Carcinoma - Dormant Projects (Contd..4), H2 2016
  • Hepatocellular Carcinoma - Dormant Projects (Contd..5), H2 2016
  • Hepatocellular Carcinoma - Dormant Projects (Contd..6), H2 2016
  • Hepatocellular Carcinoma - Dormant Projects (Contd..7), H2 2016
  • Hepatocellular Carcinoma - Dormant Projects (Contd..8), H2 2016
  • Hepatocellular Carcinoma - Dormant Projects (Contd..9), H2 2016
  • Hepatocellular Carcinoma - Dormant Projects (Contd..10), H2 2016
  • Hepatocellular Carcinoma - Discontinued Products, H2 2016
  • Hepatocellular Carcinoma - Discontinued Products (Contd..1), H2 2016
  • Hepatocellular Carcinoma - Discontinued Products (Contd..2), H2 2016
  • Hepatocellular Carcinoma - Discontinued Products (Contd..3), H2 2016

List of Figures

  • Number of Products under Development for Hepatocellular Carcinoma, H2 2016
  • Number of Products under Development for Hepatocellular Carcinoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top